Bank of Montreal
BMO
Bank of Nova Scotia
BNS
The Toronto-Dominion Bank
TD
Canadian Imperial Bank of Commerce
CM
Royal Bank of Canada
RY
CA Stock MarketDetailed Quotes
CYBN Cybin Inc
- 13.500
- +0.800+6.30%
15min DelayMarket Closed Jan 2 15:59 ET
269.90MMarket Cap-1.58P/E (TTM)
13.680High12.850Low4.06KVolume12.970Open12.700Pre Close53.74KTurnover28.12052wk High0.02%Turnover Ratio19.99MShares9.25052wk Low-8.55EPS TTM269.90MFloat Cap152.000Historical HighLossP/E (Static)19.99MShs Float9.250Historical Low-9.5EPS LYR6.54%Amplitude--Dividend TTM1.06P/B1Lot Size--Div YieldTTM
Cybin Inc News
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Cybin Inc. Advances in Mental Health Treatments
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Press Release: Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
Cybin Inc. CEO to Speak at Research Event
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Strong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management Positioning
Cybin Announces Completion of Previously Announced Share Consolidation
Cybin Inc. Shareholders Approve Key Decisions
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
Cybin Inc. Advances Neuropsychiatric Drug Development
Press Release: Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Cybin Inc: MDA EN
Trending CA Stocks
Big Five Big Five
The "Big Five" refers to Canada's five largest banks—Royal Bank of Canada, Toronto-Dominion Bank, Bank of Nova Scotia, Bank of Montreal, and Canadian Imperial Bank of Commerce—which dominate and significantly influence the country's financial sector. The "Big Five" refers to Canada's five largest banks—Royal Bank of Canada, Toronto-Dominion Bank, Bank of Nova Scotia, Bank of Montreal, and Canadian Imperial Bank of Commerce—which dominate and significantly influence the country's financial sector.